Phaseline

Companies › Jun Zhou

Jun Zhou: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IUAb190708
cytotoxic anti-PD-L1 antibody
PDCD1LG2Phase 1Solid Tumor CancerJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07584954IUAb190708Phase 1Solid Tumor CancerOncologyJun 2028

Targets

PDCD1LG2 (1)

Companies with the same targets

Biotheus FBD Biologics Boehringer Ingelheim GSK Chia Tai Tianqing Pharmaceutical Group MediLink Therapeutics (Suzhou) Pfizer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.